Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial

Mark R. Rigby, Linda A. DiMeglio, Marc S. Rendell, Eric I. Felner, Jean M. Dostou, Stephen E. Gitelman, Chetanbabu M. Patel, Kurt J. Griffin, Eva Tsalikian, Peter A. Gottlieb, Carla J. Greenbaum, Nicole A. Sherry, Wayne V. Moore, Roshanak Monzavi, Steven M. Willi, Philip Raskin, Antoinette Moran, William E. Russell, Ashley Pinckney, Lynette Keyes-ElsteinMichael Howell, Sudeepta Aggarwal, Noha Lim, Deborah Phippard, Gerald T. Nepom, James McNamara, Mario R. Ehlers

Research output: Contribution to journalArticlepeer-review

114 Scopus citations

Fingerprint

Dive into the research topics of 'Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences